Skip to main content

Advertisement

SpringerLink
Log in

Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans

  • Special Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Establishing the methods for the effective screening of compounds with optimal pharmacokinetic properties is of great importance to many scientists working in new drug discovery and development. This review deals with the methods by which in vivo pharmacokinetics in humans can be predicted from in vitro studies and from in vivo animal experiments. Direct extrapolation from animal studies to human pharmacokinetics is generally difficult because of species differences in the function of molecules involved in drug metabolism and transport. To overcome this problem, a “scaling factor,” which relates in vivo animal studies with in vitro experiments, is often used for the accurate prediction. Several experimental systems for the functional analyses of membrane transporters have been developed and many reports have revealed that various transporters clearly govern the tissue dispositions of drugs in humans. This review covers the impact of membrane transporters on the pharmacokinetics, control of elimination pathways, and toxicity. Indeed, by utilizing transporter-deficient animals, some studies have clarified the importance of transporters in various types of tissue-specific toxicity. Transporter-mediated drug–drug interactions are one of the most important issues in clinical situation because some reports suggested that severe clinical incidents are caused by the inhibition of transporter-mediated uptake and efflux in clearance organs (liver and kidney) and at several barriers. The review also focuses on the clinical significance of genetic polymorphisms of transporters, as these can influence the plasma and tissue concentrations of some drugs. Finally, integrated information is presented based on multiple in vitro studies, including those on transporters. This should enable the prediction of the outcomes of drug exposure in cells, tissues, and individual organisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  • Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685–691

    Article  PubMed  CAS  Google Scholar 

  • Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577–2582

    Article  PubMed  CAS  Google Scholar 

  • Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Muller M (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78:182–190

    Article  PubMed  CAS  Google Scholar 

  • Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”. Clin Pharmacol Ther 74:437–447

    Article  PubMed  CAS  Google Scholar 

  • Cui Y, Konig J, Keppler D (2001) Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60:934–943

    PubMed  CAS  Google Scholar 

  • Endres CJ, Hsiao P, Chung FS, Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501–517

    Article  PubMed  CAS  Google Scholar 

  • Enokizono J, Kusuhara H, Sugiyama Y (2007) Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72:967–975

    Article  PubMed  CAS  Google Scholar 

  • Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62:365–376

    Article  PubMed  CAS  Google Scholar 

  • Giacomini KM, Sugiyama Y (2005) Membrane transporters and drug response. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. 11th edn. McGraw-Hill, New York, pp 41–70

    Google Scholar 

  • Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800–807

    PubMed  CAS  Google Scholar 

  • Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y, Niinuma K, Suzuki H, Sugiyama Y (1997) Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 280:1304–1311

    PubMed  CAS  Google Scholar 

  • Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749–757

    Article  PubMed  CAS  Google Scholar 

  • Konig J, Seithel A, Gradhand U, Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg’s Arch Pharmacol 372:432–443

    Article  CAS  Google Scholar 

  • Kopplow K, Letschert K, Konig J, Walter B, Keppler D (2005) Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 68:1031–1038

    Article  PubMed  CAS  Google Scholar 

  • Kusuhara H, Sugiyama Y (2005) Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73–85

    Article  PubMed  Google Scholar 

  • Lau YY, Huang Y, Frassetto L, Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204

    Article  PubMed  CAS  Google Scholar 

  • Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, Suhara T (2006) In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 316:647–653

    Article  PubMed  CAS  Google Scholar 

  • Letschert K, Komatsu M, Hummel-Eisenbeiss J, Keppler D (2005) Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2. J Pharmacol Exp Ther 313:549–556

    Article  PubMed  CAS  Google Scholar 

  • Maeda K, Sugiyama Y (2007) In vitro-in vivo scale-up of drug transport activities. In: You G, Morris ME (eds) Drug transporters. Wiley, New Jersey, pp 557–588

    Chapter  Google Scholar 

  • Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y (2006) Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–439

    Article  PubMed  CAS  Google Scholar 

  • Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin–Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059–1067

    Article  PubMed  CAS  Google Scholar 

  • Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251–261

    Article  PubMed  CAS  Google Scholar 

  • Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–1324

    PubMed  CAS  Google Scholar 

  • Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ (2005a) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–478

    Article  PubMed  CAS  Google Scholar 

  • Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm M (2005b) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602–604

    Article  PubMed  CAS  Google Scholar 

  • Niemi M, Pasanen MK, Neuvonen PJ (2006) SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356–366

    Article  PubMed  CAS  Google Scholar 

  • Nies AT, Herrmann E, Brom M, Keppler D (2008) Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn-Schmiedeberg’s Arch Pharmacol 376:449–461

    Article  CAS  Google Scholar 

  • Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565

    Article  PubMed  CAS  Google Scholar 

  • Oguchi H, Miyasaka M, Koiwai T, Tokunaga S, Hora K, Sato K, Yoshie T, Shioya H, Furuta S (1993) Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 24:421–427

    PubMed  CAS  Google Scholar 

  • Omote H, Hiasa M, Matsumoto T, Otsuka M, Moriyama Y (2006) The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 27:587–593

    Article  PubMed  CAS  Google Scholar 

  • Petzinger E, Geyer J (2006) Drug transporters in pharmacokinetics. Naunyn-Schmiedeberg’s Arch Pharmacol 372:465–475

    Article  CAS  Google Scholar 

  • Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–148

    Article  PubMed  CAS  Google Scholar 

  • Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497–6503

    Article  PubMed  CAS  Google Scholar 

  • Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y (2004) Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 66:450–459

    Article  PubMed  CAS  Google Scholar 

  • Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD (2006) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503–514

    Article  CAS  Google Scholar 

  • Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524

    Article  PubMed  CAS  Google Scholar 

  • Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71–105

    Article  PubMed  CAS  Google Scholar 

  • Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616

    Article  PubMed  CAS  Google Scholar 

  • Shitara Y, Hirano M, Sato H, Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236

    Article  PubMed  CAS  Google Scholar 

  • Shitara Y, Horie T, Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–446

    Article  PubMed  CAS  Google Scholar 

  • Sugiyama Y (2005) Druggability: selecting optimized drug candidates. Drug Discov Today 10:1577–1579

    Article  PubMed  Google Scholar 

  • Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, Sugiyama Y (2005a) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337–345

    Article  PubMed  CAS  Google Scholar 

  • Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y (2005b) Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res 22:647–660

    Article  PubMed  CAS  Google Scholar 

  • Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y (2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 47:1427–1433

    PubMed  CAS  Google Scholar 

  • Tanaka E, Kurata N, Yasuhara H (2003) How useful is the “cocktail approach” for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 28:157–165

    Article  PubMed  CAS  Google Scholar 

  • Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675

    Article  PubMed  CAS  Google Scholar 

  • Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510–515

    Article  PubMed  CAS  Google Scholar 

  • Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y (2003) Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63:844–848

    Article  PubMed  CAS  Google Scholar 

  • Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–1254

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY, Wang LC, Fan L, Wang A, Zhou HH (2007) SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 64:346–352

    Article  PubMed  CAS  Google Scholar 

Download references

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Author information

Authors and Affiliations

  1. Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

    Satoshi Kitamura, Kazuya Maeda & Yuichi Sugiyama

Authors
  1. Satoshi Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuya Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuichi Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuichi Sugiyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitamura, S., Maeda, K. & Sugiyama, Y. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn-Schmied Arch Pharmacol 377, 617–628 (2008). https://doi.org/10.1007/s00210-008-0312-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-008-0312-9

Keywords

Search

Navigation